232 related articles for article (PubMed ID: 31586229)
1. Addition of chemotherapy to hyperfractionated radiotherapy in advanced head and neck cancer-a meta-analysis.
Haussmann J; Tamaskovics B; Bölke E; Djiepmo-Njanang FJ; Kammers K; Corradini S; Hautmann M; Ghadjar P; Maas K; Schuler PJ; Hoffmann TK; Lammering G; Budach W; Matuschek C
Strahlenther Onkol; 2019 Dec; 195(12):1041-1049. PubMed ID: 31586229
[TBL] [Abstract][Full Text] [Related]
2. Hyperfractionated radiation therapy with or without concurrent low-dose daily cisplatin in locally advanced squamous cell carcinoma of the head and neck: a prospective randomized trial.
Jeremic B; Shibamoto Y; Milicic B; Nikolic N; Dagovic A; Aleksandrovic J; Vaskovic Z; Tadic L
J Clin Oncol; 2000 Apr; 18(7):1458-64. PubMed ID: 10735893
[TBL] [Abstract][Full Text] [Related]
3. Induction chemotherapy followed by concurrent radio-chemotherapy versus concurrent radio-chemotherapy alone as treatment of locally advanced squamous cell carcinoma of the head and neck (HNSCC): A meta-analysis of randomized trials.
Budach W; Bölke E; Kammers K; Gerber PA; Orth K; Gripp S; Matuschek C
Radiother Oncol; 2016 Feb; 118(2):238-43. PubMed ID: 26589131
[TBL] [Abstract][Full Text] [Related]
4. Radiation therapy with or without concurrent low-dose daily chemotherapy in locally advanced, nonmetastatic squamous cell carcinoma of the head and neck.
Jeremic B; Milicic B; Dagovic A; Vaskovic Z; Tadic L
J Clin Oncol; 2004 Sep; 22(17):3540-8. PubMed ID: 15337803
[TBL] [Abstract][Full Text] [Related]
5. Docetaxel, cisplatin and 5-fluorouracil induction chemotherapy followed by chemoradiotherapy or chemoradiotherapy alone in stage III-IV unresectable head and neck cancer: Results of a randomized phase II study.
Takácsi-Nagy Z; Hitre E; Remenár É; Oberna F; Polgár C; Major T; Gödény M; Fodor J; Kásler M
Strahlenther Onkol; 2015 Aug; 191(8):635-41. PubMed ID: 25782685
[TBL] [Abstract][Full Text] [Related]
6. Systematic Review and Meta-analysis of Conventionally Fractionated Concurrent Chemoradiotherapy versus Altered Fractionation Radiotherapy Alone in the Definitive Management of Locoregionally Advanced Head and Neck Squamous Cell Carcinoma.
Gupta T; Kannan S; Ghosh-Laskar S; Agarwal JP
Clin Oncol (R Coll Radiol); 2016 Jan; 28(1):50-61. PubMed ID: 26454839
[TBL] [Abstract][Full Text] [Related]
7. Concurrent hyperfractionated accelerated radiotherapy with 5-FU and once weekly cisplatin in locally advanced head and neck cancer. The 10-year results of a prospective phase II trial.
Budach V; Becker ET; Boehmer D; Badakhshi H; Jahn U; Wernecke KD; Stromberger C
Strahlenther Onkol; 2014 Mar; 190(3):250-5. PubMed ID: 24322993
[TBL] [Abstract][Full Text] [Related]
8. Concurrent use of cisplatin or cetuximab with definitive radiotherapy for locally advanced head and neck squamous cell carcinomas.
Levy A; Blanchard P; Bellefqih S; Brahimi N; Guigay J; Janot F; Temam S; Bourhis J; Deutsch E; Daly-Schveitzer N; Tao Y
Strahlenther Onkol; 2014 Sep; 190(9):823-31. PubMed ID: 24638267
[TBL] [Abstract][Full Text] [Related]
9. Final Results of a Randomized Phase 2 Trial Investigating the Addition of Cetuximab to Induction Chemotherapy and Accelerated or Hyperfractionated Chemoradiation for Locoregionally Advanced Head and Neck Cancer.
Seiwert TY; Melotek JM; Blair EA; Stenson KM; Salama JK; Witt ME; Brisson RJ; Chawla A; Dekker A; Lingen MW; Kocherginsky M; Villaflor VM; Cohen EE; Haraf DJ; Vokes EE
Int J Radiat Oncol Biol Phys; 2016 Sep; 96(1):21-9. PubMed ID: 27511844
[TBL] [Abstract][Full Text] [Related]
10. Impact of adding concurrent chemotherapy to hyperfractionated radiotherapy for locally advanced non-small cell lung cancer (NSCLC): comparison of RTOG 83-11 and RTOG 91-06.
Komaki R; Scott C; Lee JS; Urtasun RC; Byhardt RW; Emami B; Andras EJ; Asbell SO; Rotman M; Cox JD
Am J Clin Oncol; 1997 Oct; 20(5):435-40. PubMed ID: 9345325
[TBL] [Abstract][Full Text] [Related]
11. Weekly Low-Dose Versus Three-Weekly High-Dose Cisplatin for Concurrent Chemoradiation in Locoregionally Advanced Non-Nasopharyngeal Head and Neck Cancer: A Systematic Review and Meta-Analysis of Aggregate Data.
Szturz P; Wouters K; Kiyota N; Tahara M; Prabhash K; Noronha V; Castro A; Licitra L; Adelstein D; Vermorken JB
Oncologist; 2017 Sep; 22(9):1056-1066. PubMed ID: 28533474
[TBL] [Abstract][Full Text] [Related]
12. Locally advanced squamous cell carcinoma of the head and neck: A systematic review and Bayesian network meta-analysis of the currently available treatment options.
Iocca O; Farcomeni A; Di Rocco A; Di Maio P; Golusinski P; Pardiñas López S; Savo A; Pellini R; Spriano G
Oral Oncol; 2018 May; 80():40-51. PubMed ID: 29706187
[TBL] [Abstract][Full Text] [Related]
13. Phase III randomized trial of preoperative concurrent chemoradiotherapy versus preoperative radiotherapy for patients with locally advanced head and neck squamous cell carcinoma.
Yi J; Huang X; Xu Z; Liu S; Wang X; He X; Luo D; Luo J; Xiao J; Zhang S; Wang K; Qu Y; Tang Y; Liu W; Xu G; Gao L; Wang D
Oncotarget; 2017 Jul; 8(27):44842-44850. PubMed ID: 28179586
[TBL] [Abstract][Full Text] [Related]
14. Aggressive concurrent chemoradiotherapy for squamous cell head and neck cancer: an 8-year single-institution experience.
Lavertu P; Adelstein DJ; Saxton JP; Secic M; Eliachar I; Strome M; Larto MA; Wood BG
Arch Otolaryngol Head Neck Surg; 1999 Feb; 125(2):142-8. PubMed ID: 10037279
[TBL] [Abstract][Full Text] [Related]
15. Hyperfractionated accelerated radiation therapy plus cetuximab plus cisplatin chemotherapy in locally advanced inoperable squamous cell carcinoma of the head and neck : Final 5‑year results of a phase II study.
Kuhnt T; Schreiber A; Pirnasch A; Hautmann MG; Hass P; Sieker FP; Engenhart-Cabillic R; Richter M; Dellas K; Dunst J
Strahlenther Onkol; 2017 Sep; 193(9):733-741. PubMed ID: 28500491
[TBL] [Abstract][Full Text] [Related]
16. Prospective phase II trial of cetuximab plus VMAT-SIB in locally advanced head and neck squamous cell carcinoma. Feasibility and tolerability in elderly and chemotherapy-ineligible patients.
Alongi F; Bignardi M; Garassino I; Pentimalli S; Cavina R; Mancosu P; Reggiori G; Poletti A; Ferrari D; Foa P; Bigoni A; Dragonetti A; Salvatori P; Spahiu O; Fogliata A; Cozzi L; Santoro A; Scorsetti M
Strahlenther Onkol; 2012 Jan; 188(1):49-55. PubMed ID: 22194030
[TBL] [Abstract][Full Text] [Related]
17. Predictors of severe late radiotherapy-related toxicity after hyperfractionated radiotherapy with or without concomitant cisplatin in locally advanced head and neck cancer. Secondary retrospective analysis of a randomized phase III trial (SAKK 10/94).
Ghadjar P; Simcock M; Zimmermann F; Betz M; Bodis S; Bernier J; Studer G; Aebersold DM;
Radiother Oncol; 2012 Aug; 104(2):213-8. PubMed ID: 22726581
[TBL] [Abstract][Full Text] [Related]
18. From conventionally fractionated radiation therapy to hyperfractionated radiation therapy alone and with concurrent chemotherapy in patients with early-stage nonsmall cell lung cancer.
Jeremić B; Milicić B
Cancer; 2008 Feb; 112(4):876-84. PubMed ID: 18172901
[TBL] [Abstract][Full Text] [Related]
19. Cetuximab and Radiotherapy Versus Cisplatin and Radiotherapy for Locally Advanced Head and Neck Cancer: A Randomized Phase II Trial.
Magrini SM; Buglione M; Corvò R; Pirtoli L; Paiar F; Ponticelli P; Petrucci A; Bacigalupo A; Crociani M; Lastrucci L; Vecchio S; Bonomo P; Pasinetti N; Triggiani L; Cavagnini R; Costa L; Tonoli S; Maddalo M; Grisanti S
J Clin Oncol; 2016 Feb; 34(5):427-35. PubMed ID: 26644536
[TBL] [Abstract][Full Text] [Related]
20. Toxicity of concurrent hyperfractionated radiation therapy and chemotherapy in locally advanced (stage III) non-small cell lung cancer (NSCLC): single institution experience in 600 patients.
Jeremić B; Miličić B; Milisavljevic S
Clin Transl Oncol; 2012 Aug; 14(8):613-8. PubMed ID: 22855143
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]